- Home
- PHAT vs SKYH Comparison
PHAT vs SKYH Comparison
Compare PHAT & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- SKYH
- Stock Information
- Founded
- PHAT 2018
- SKYH 2017
- Country
- PHAT United States
- SKYH United States
- Employees
- PHAT N/A
- SKYH N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- SKYH Military/Government/Technical
- Sector
- PHAT Health Care
- SKYH Industrials
- Exchange
- PHAT Nasdaq
- SKYH Nasdaq
- Market Cap
- PHAT 465.0M
- SKYH 389.8M
- IPO Year
- PHAT 2019
- SKYH N/A
- Fundamental
- Price
- PHAT $6.96
- SKYH $11.35
- Analyst Decision
- PHAT Strong Buy
- SKYH Strong Buy
- Analyst Count
- PHAT 4
- SKYH 2
- Target Price
- PHAT $23.00
- SKYH $15.50
- AVG Volume (30 Days)
- PHAT 971.9K
- SKYH 110.1K
- Earning Date
- PHAT 03-06-2025
- SKYH 11-12-2024
- Dividend Yield
- PHAT N/A
- SKYH N/A
- EPS Growth
- PHAT N/A
- SKYH N/A
- EPS
- PHAT N/A
- SKYH N/A
- Revenue
- PHAT $26,270,000.00
- SKYH $12,357,000.00
- Revenue This Year
- PHAT $7,622.43
- SKYH $91.88
- Revenue Next Year
- PHAT $236.87
- SKYH $112.98
- P/E Ratio
- PHAT N/A
- SKYH N/A
- Revenue Growth
- PHAT N/A
- SKYH 107.82
- 52 Week Low
- PHAT $6.07
- SKYH $8.26
- 52 Week High
- PHAT $19.71
- SKYH $14.52
- Technical
- Relative Strength Index (RSI)
- PHAT 37.02
- SKYH 42.03
- Support Level
- PHAT $6.36
- SKYH $10.83
- Resistance Level
- PHAT $7.20
- SKYH $12.22
- Average True Range (ATR)
- PHAT 0.48
- SKYH 0.40
- MACD
- PHAT 0.08
- SKYH -0.08
- Stochastic Oscillator
- PHAT 30.48
- SKYH 27.61
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.